Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 1989 Jul;17(1):53-63.
doi: 10.2165/00003088-198917010-00005.

Population pharmacokinetic analysis of bisoprolol

Affiliations
Clinical Trial

Population pharmacokinetic analysis of bisoprolol

J Grevel et al. Clin Pharmacokinet. 1989 Jul.

Abstract

The technique of population pharmacokinetic analysis was employed to study the variability in the dose concentration relationship of bisoprolol during its clinical development. The influence of demographic factors on the variability of clearance was investigated in 3 different populations: group I, patients (including an elderly group) with essential hypertension receiving multiple oral doses of bisoprolol 10 or 20mg for 3 months; group II, patients with different degrees of renal impairment and healthy controls; and group III, patients with different types of hepatic impairment and healthy controls. Patients and controls in groups II and III received only a single oral dose of bisoprolol 10mg. The 3 data sets were analysed separately, using a non-linear mixed effects model (the NONMEM program). A 2-compartment pharmacokinetic model with first-order absorption described the data adequately. The typical values of volume of central compartment, volume of distribution at steady-state and the absorption rate constant for the 3 populations were: for group I, 68L, 235L, and 0.7h-1; for group II, 28L, 179L, and 0.3h-1; and for group III, 55L, 256L, and 0.4h-1, respectively. Plasma clearance was related to age in group I, to serum creatinine in group II and to aspartate transaminase activity in group III. The 68% confidence limits for clearance and elimination half-life were 8.2 to 21.5 L/h and 7.6 to 19.7h, respectively, for 50-year-old patients in group I. The analysis predicted that progressive increases in serum creatinine or aspartate transaminase activity will result in only a 50% reduction of clearance.

PubMed Disclaimer

Similar articles

Cited by

References

    1. J Cardiovasc Pharmacol. 1986;8 Suppl 11:S21-8 - PubMed
    1. J Cardiovasc Pharmacol. 1986;8 Suppl 6:S16-9 - PubMed
    1. J Pharmacokinet Biopharm. 1977 Oct;5(5):445-79 - PubMed
    1. Clin Pharmacol Ther. 1985 Nov;38(5):481-7 - PubMed
    1. Clin Pharmacokinet. 1987 Aug;13(2):110-7 - PubMed

Publication types

LinkOut - more resources